Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752726 · ClinicalTrials.gov registry record · Phase 4
Effect of Orlistat in Body Composition
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 131
- Enrollment target
NCT00752726 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 131 participants.
The verdict
NCT00752726, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a 24 week weight loss program with orlistat 60 mg will produce greater changes in body composition compared to placebo.
Interventions
- DRUG Placebo
- DRUG Orlistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00752726
The ClinicalTrials.gov registry entry for NCT00752726 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00752726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00752726 about?
NCT00752726 is a clinical study titled "Effect of Orlistat in Body Composition". The purpose of this study is to determine if a 24 week weight loss program with orlistat 60 mg will produce greater changes in body composition compared to placebo.
What is the current status of trial NCT00752726?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2008-09. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00752726?
The interventions under investigation include: Placebo (DRUG), Orlistat (DRUG).
Who is sponsoring clinical trial NCT00752726?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.